Analysts expect DNA X, Inc. to report revenue of 33.92 M for Q1 26, against a range of 32.35 M to 35.49 M. The most recent reported quarter, Q3 25, came in at 16.21 M, a 51.4% miss against the 33.35 M consensus.
| Metric | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 16.78 M | 11.50 M | 15.02 M | 15.00 M | 16.72 M | 11.20 M | 16.21 M | - | - | - | - | - | - | - | - |
| High Estimate | 18.66 M | 12.40 M | 15.45 M | 19.21 M | 26.58 M | 30.26 M | 36.36 M | 35.49 M | 39.02 M | 41.06 M | 36.74 M | 51.81 M | 67.77 M | 73.55 M | 66.72 M |
| Low Estimate | 16.24 M | 10.88 M | 12.68 M | 17.27 M | 22.69 M | 25.71 M | 30.33 M | 32.35 M | 36.70 M | 33.95 M | 33.32 M | 47.82 M | 60.44 M | 61.81 M | 60.37 M |
| Consensus Estimate | 17.45 M | 11.64 M | 14.07 M | 18.24 M | 24.64 M | 27.98 M | 33.35 M | 33.92 M | 37.86 M | 37.51 M | 35.03 M | 49.82 M | 64.11 M | 67.68 M | 63.55 M |
Analysts expect DNA X, Inc. to report earnings per share of 5.43 for Q2 26, against a range of 4.95 to 5.91. The most recent reported quarter, Q1 26, came in at 8.12, a 54.3% beat against the 5.26 consensus.
| Metric | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -12.60 | -25.38 | -9.36 | -81.00 | 1.44 | -14.22 | -4.83 | 8.12 | - | - | - | - | - | - | - |
| High Estimate | -4.97 | -8.61 | -11.53 | -6.97 | -2.34 | 0.79 | 5.42 | 5.75 | 5.91 | 5.09 | 5.43 | 46.09 | 27.67 | 21.67 | -13.26 |
| Low Estimate | -5.35 | -9.95 | -13.57 | -8.15 | -2.54 | 0.69 | 4.76 | 4.77 | 4.95 | 4.37 | 4.89 | 37.91 | 25.91 | 17.87 | -15.34 |
| Consensus Estimate | -5.16 | -9.28 | -12.55 | -7.56 | -2.44 | 0.74 | 5.09 | 5.26 | 5.43 | 4.73 | 5.16 | 42.00 | 26.79 | 19.77 | -14.30 |